Nrx pharmaceuticals announces the appointment of carrie m. carretta, phd, apn-bc, ahn-bc, pmhnp, senior vice president of clinical development and medical affairs

Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs focused psychiatry practice expert in ptsd, affective disorders and schizophrenia proven track record in research as an investigator and academic grant-funded researcher visiting scholar  at stanford university, center for precision mental health and wellness former roles at boehringer ingelheim and pendulum therapeutics radnor, pa. , dec. 5, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage central nervous system (cns) biopharmaceutical company, today announced the appointment of carrie m.
NRXP Ratings Summary
NRXP Quant Ranking